Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.
about
Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients.Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials.Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone.
P2860
Q28081266-7EF81645-79DF-4AA6-8B79-3941DA4B3D8BQ34134900-F10E4CA5-0EDD-4FE0-848F-33004412BEFBQ34251223-1705D2FD-E322-4DB3-A33F-D5A98E49B2A7Q35539510-05C6866C-EEB2-4BEC-BE32-6F0E39E77063Q37501229-5AEABD4B-445F-4CE7-B687-704CA60CE116Q37696578-E2BAF574-94E8-47F1-9B29-2A11AA1158F2Q38811335-B497933C-180F-4795-9402-BF85BCD3AE46Q38865547-8D9F1F73-CEB7-45D8-B166-B34062A42C09Q42209719-F213E625-C2DC-4556-B0AB-97F8A0392CCA
P2860
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Lopinavir/ritonavir, atazanavi ...... l randomized controlled trial.
@en
Lopinavir/ritonavir, atazanavi ...... l randomized controlled trial.
@nl
type
label
Lopinavir/ritonavir, atazanavi ...... l randomized controlled trial.
@en
Lopinavir/ritonavir, atazanavi ...... l randomized controlled trial.
@nl
prefLabel
Lopinavir/ritonavir, atazanavi ...... l randomized controlled trial.
@en
Lopinavir/ritonavir, atazanavi ...... l randomized controlled trial.
@nl
P2093
P2860
P1476
Lopinavir/ritonavir, atazanavi ...... l randomized controlled trial.
@en
P2093
Anders Blaxhult
Anders Sönnerborg
Jan Vesterbacka
Lars-Magnus Andersson
Leo Flamholc
Magnus Gisslén
Vidar Ormaasen
P2860
P304
P356
10.3109/00365548.2012.756985
P577
2013-01-07T00:00:00Z